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More than 800,000 North Americans are admitted to the
hospital each year with an acute myocardial infarction (MI)
(1,2). Most of these patients survive until hospital discharge,
but a substantial number of the survivors will die of
out-of-hospital arrhythmic events (3). Approximately half
the deaths that occur following acute MI are attributable to
recurrent ischemic events or to congestive heart failure
related to left ventricular impairment (3,4). A plethora of
clinical trials and guideline statements have addressed the
issue of post-MI risk stratification with respect to these
complications. However, lethal arrhythmias cause approxi-
mately half the deaths that occur during the first year after
acute MI (5,6). Unfortunately, little information is available
to guide us in the appropriate stratification of patients at risk
for this complication.
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Various tests have been proposed as being useful for
post-MI stratification of patients at risk of major arrhythmic
events. Investigators have found that measures of left
ventricular function are particularly useful (7). Other tests
that have been closely examined include signal-averaged
electrocardiogram (SAECG) (8) and Holter monitoring.
Several aspects of Holter monitoring have been correlated
with the risk of arrhythmic events, including the incidence
of premature ventricular contractions, the occurrence of
major arrhythmias and a reduction in heart rate variability
(HRV) (9). Electrophysiologic studies are thought to be
especially predictive (10). More recently, various other
techniques have been examined as possible predictors,
including baroreflex sensitivity (11), QT dispersion (12),
T-wave alternans (13), time-domain analysis (14), spectral
turbulence analysis (14) and fractal dimension (15).
Because no single diagnostic test has been found to have
adequate predictive ability, investigators have examined the
ability of various combinations of tests to predict arrhythmic
events in the post-MI population. Based on the results of
these studies, a number of testing algorithms have been
proposed that combine the use of left ventricular ejection
fraction (LVEF), SAECG, HRV and electrophysiologic
studies (16–21). Because of the cost and invasive nature of
electrophysiologic studies, this test is usually reserved for the
end of the algorithm when it can be used in small numbers
of high-risk patients. Unfortunately, previous studies that
examined combinations of tests were done in relatively small
numbers of patients at a limited number of clinical centers.
These studies had the advantage of performing several types
of tests in the same patient population, but the studies were
limited because of their size and generalizability. In this
context, the report by Bailey et al. (22) in this issue of the
Journal is a welcome addition to the rather limited data that
are currently available.
The objective of the study by Bailey et al. (22) was to
identify a staged approach to post-MI risk stratification
with respect to arrhythmic events. To that end, the inves-
tigators performed a literature review to identify studies
assessing the predictive abilities of five different tests for the
identification of major arrhythmic events (SAECG, severe
ventricular arrhythmias on Holter monitoring, HRV,
LVEF and electrophysiologic study). Sensitivities and spec-
ificities for the five tests were pooled from 44 reports. Point
estimates for the sensitivities and specificities were deter-
mined as well as 95% confidence intervals (CIs). The
researchers then assessed various combinations of these tests
to determine which staged application would afford the
most efficient use of resources and be the most effective in
identifying those patients who would benefit from the
insertion of an implantable cardioverter-defibrillator (ICD).
Finally, Bailey et al. (22) performed an analysis to determine
the cost of a staged approach to risk stratification.
The pooled results of their study demonstrated that the
sensitivities for the five diagnostic tests ranged from 42.8%
to 62.4%, and the specificities ranged from 77.4% to 85.8%.
From these results, the investigators identified a three-stage
risk-stratification approach. This approach involves screen-
ing all post-MI patients with a SAECG as well as a measure
of LVEF. Patients who are judged to be high risk by both
studies receive an ICD; low-risk patients undergo no further
risk stratification; and intermediate-risk patients undergo
Holter monitoring both for examination of HRV and to
detect the occurrence of significant ventricular arrhythmias.
If the Holter is positive, the patient receives an ICD; if it is
negative, the patient undergoes no further testing; and if it
is indeterminate, the patient undergoes an electrophysi-
ologic study. The investigators calculate that the risk-
stratification approach that they advocate will lead to 11.8%
of post-MI patients being identified as being likely candi-
dates for an ICD (41.4% risk of major arrhythmic events at
two years); 80.0% being identified as low risk and not
requiring an ICD (2.9% risk at two years); and 8.2% of
patients being identified as intermediate risk (8.9% risk at
two years). The cost of this staged approach is estimated to
be $415 per patient.
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Although previous studies examined the utility of
post-MI risk stratification, the study by Bailey et al. (22)
highlights several important issues that deserve attention.
First, their study involves a meta-analysis of previous studies
that examined diagnostic tests thought to identify patients
at high risk of arrhythmic events. In comparison with
previous studies, Bailey et al. (22) performed pooled analy-
ses to determine estimates of sensitivity and specificity for
the diagnostic tests they examined. These pooled analyses
involved large numbers of subjects, ranging from 4,022
patients for electrophysiologic studies to 9,883 patients for
studies involving SAECG. As a consequence, the test
characteristics that the investigators report may be more
precise and more generalizable than the test characteristics
reported by previous investigators.
To obtain reliable pooled estimates of sensitivity and
specificity, meta-analyses of diagnostic test results must be
performed in a rigorous manner (23,24). Similar to meta-
analyses of clinical trial results, meta-analyses of diagnostic
test results require meticulous attention to the identification
of studies to be included, data abstraction and data pooling.
When identifying potential studies for inclusion, for exam-
ple, every effort should be made to identify all studies in the
area—whether positive or negative. Thus, in addition to
searching the English and non-English medical literature,
authors of prior studies should be contacted to see if they are
aware of unpublished studies examining the area of interest.
Publication bias, in which negative studies are less likely to
be published, can lead to an overestimation of the utility of
a diagnostic test (25,26). Once thorough efforts have led to
the identification of all potential studies, blinded reviewers
should independently examine the candidate studies using
systematic inclusion and exclusion criteria. Only when the
reviewers agree does a candidate study come to be included
in the meta-analysis. Once a study is included, the reviewers
should independently abstract the data. For meta-analyses
of diagnostic tests, particular attention must be paid to the
definitions used by the investigators to define positive and
negative test results. Finally, once the data have been
abstracted, specific methods should be used to pool the
characteristics of the diagnostic tests (27). Even after closely
following the above steps, investigators have noted differ-
ences in the results of meta-analyses on the same subject,
and meta-analyses that pooled large numbers of patients
have been found to differ with subsequent large clinical trials
(24,28).
Although the techniques used by Bailey et al. (22) largely
conform to previous recommendations regarding the con-
duct of meta-analyses, several exceptions are present. For
example, the investigators limited their literature search to
English-language studies, and they do not appear to have
contacted previous researchers about the existence of un-
published studies. The studies of diagnostic tests that they
pooled varied in terms of the cut points used to determine
a positive test, and importantly, these tests were adminis-
tered to patients at varying times after their MIs. No
blinding of the data abstracters appears to have been
employed, and the methods that were used for the data
pooling are somewhat unclear. In most meta-analyses of this
type, a random effects model is used (27). If there is
homogeneity among the studies, then the model will reduce
to one that assumes homogeneity; if not, the between-study
variation will automatically be incorporated into the model.
Because several methodologic limitations are present in
their meta-analysis, the investigators may have overesti-
mated the sensitivities and specificities of the tests they
examined.
A second issue is that even with the large numbers of
patients included in their pooled analyses, because there
were major variations among the individual studies, the 95%
CIs for the pooled sensitivities and specificities were wide
(Table 1). The staged approach to risk stratification advo-
cated by Bailey et al. (22) is based on their point estimates
for sensitivity and specificity. However, their conclusions
may not be robust given the wide and overlapping ranges
within which the true sensitivities and specificities for these
tests lie. A sensitivity analysis might have been helpful in
this regard. By varying the sensitivities and specificities used
in their calculations between the extremes of the 95% CIs,
the investigators would have been able to examine whether
their conclusions were indeed robust.
A third issue to be considered is that the investigators
reported for each diagnostic test the two-year probability of
a major arrhythmic event if the test was positive (also known
as the positive predictive value) or if the test was negative
(equivalent to 100  negative predictive value). However,
because these test characteristics vary with the prior proba-
bility of disease, so as to ensure comparability between tests,
Table 1. Characteristics of the Five Diagnostic Tests (Assuming a Prior Probability of 7.9%)
Sensitivity (%)
[95% CI]
Specificity (%)
[95% CI]
Positive
Predictive
Value (%)
Negative
Predictive
Value (%) Accuracy (%)
Positive
Likelihood
Ratio
Negative
Likelihood
Ratio
SAECG 62.4 [56.4–67.9] 77.4 [73.6–80.8] 19.1 96.0 76.2 2.8 0.5
SVA 42.8 [32.7–53.7] 80.9 [75.0–85.7] 16.1 94.3 77.9 2.2 0.7
HRV 49.8 [37.5–62.1] 85.8 [82.1–88.9] 23.1 95.2 83.0 3.5 0.6
LVEF 59.1 [53.1–64.6] 77.8 [75.5–79.9] 18.6 95.7 76.3 2.7 0.5
EPS 61.6 [48.2–73.4] 84.1 [65.0–93.8] 24.9 96.2 82.3 3.9 0.5
EPS  electrophysiologic study; HRV  heart rate variability; LVEF  left ventricular ejection fraction; SAECG  signal-averaged electrocardiogram; SVA  significant
ventricular arrhythmia on Holter monitoring.
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these characteristics should be calculated using the same
prior probability of disease. After recalculating these test
characteristics using a prior probability of 7.9% for each of
the tests (Table 1), we can see that the ability of these
individual tests to distinguish high-risk patients is similar
and remarkably poor. These results are confirmed when the
accuracy and the positive and negative likelihood ratios are
calculated. Accuracy is an overall measure of how well a
diagnostic test performs. It is a composite measure of how
frequently a diagnostic test correctly identifies patients with
and without a disease or condition. The positive likelihood
ratio is the odds that a patient with a disease will have a
positive test divided by the odds that a patient without the
disease will have a positive result. The negative likelihood
ratio is the odds that a patient with a disease will have a
negative test divided by the odds that a patient without the
disease will have a negative result. Similar to sensitivity and
specificity, likelihood ratios do not vary with different
pretest probabilities of disease. When the above test char-
acteristics are calculated, we again see that none of the
diagnostic tests examined are exceptional predictors of
which patients will go on to have arrhythmic events. In
addition, although HRV and electrophysiologic studies may
be modestly better tests, overall these tests are quite similar
in their predictive abilities. It is for this reason that various
investigators have attempted to devise a sequence of tests
that will provide a better prediction than any one of the tests
alone.
Thus, a fourth issue is the methodology by which the
predictive value of combinations of tests is determined.
Generally speaking, when we employ a combination or a
sequence of diagnostic tests, we try to optimize the overall
sensitivity and specificity of the combination. When screen-
ing for HIV, for example, we initially use a test with high
sensitivity and low specificity so as not to miss any patients
who might have the disease. For those patients who have a
positive test, a second diagnostic test with high specificity is
then required to confirm the diagnosis. In this way, we can
efficiently identify patients with HIV even though the two
tests individually may not have adequate discriminatory
ability.
In the case of tests used to predict major arrhythmic
events, however, we can see that each of the tests has low
sensitivities and only modest specificities. Thus, it is hard to
imagine how any combination of these tests will lead to a
truly effective identification of patients at risk. Even with
the staged approach advocated by the investigators (22),
11.8% of all post-MI patients will require an ICD, and
58.6% of these patients will not benefit from it. In addition,
the optimal discriminative ability of a combination of tests
occurs when there is no interdependence between the tests
(29). For example, exercise treadmill testing and echocar-
diographic measurement of LVEF are likely to provide
independent prognostic information after acute MI. The
use, however, of HRV and identification of serious ventric-
ular arrhythmias on the same Holter monitor may not
provide completely independent prognostic information.
Because Bailey et al. (22) assumed independence between
the diagnostic tests used in their study, the prognostic ability
of their staged approach may well be overestimated.
Finally, three practical issues deserve mention: 1) the
relationship between ischemia and arrhythmic events; 2) the
timing of the diagnostic tests; and 3) the cost of applying the
risk-stratification approach advocated by the investigators.
Perhaps the most important cause of major arrhythmic
events in the post-MI population is myocardial ischemia.
Most of the studies that were pooled by Bailey et al. (22)
examined groups of patients in whom residual ischemia had
already been excluded. Because ischemia is such a common
cause of arrhythmic events, any staged approach to risk
stratification must take this etiology into account. It is for
this reason that most electrophysiologists are reluctant to
employ the diagnostic tests examined by the investigators
until the absence of residual ischemia has been confirmed.
The timing of diagnostic testing after MI is also impor-
tant. A practical, population-based risk-stratification
scheme would need to be performed in hospital while
patients are recovering from an MI. However, diagnostic
testing in the acute and subacute MI setting may not be
predictive of out-of-hospital arrhythmic events. Testing
patients after discharge, however, is impractical and likely to
be associated with low rates of compliance.
Finally, cost is a major factor limiting the application of
the investigators’ risk-stratification approach. Several stud-
ies suggest that the cost associated with implantation of an
ICD is$30,000 (30,31). This figure only includes the cost
of the device, the implantation procedure, and the in-
hospital stay. Additional costs are incurred during the
follow-up period with regular maintenance, battery replace-
ments, and so forth. Using the approach advocated by Bailey
et al. (22), 11.8% of post-MI patients would be identified as
benefiting from a prophylactic ICD insertion. If more than
800,000 North Americans are admitted to hospital each
year with acute MI, this approach would identify 80,000
patients who would require ICD insertion. At a cost of
$30,000/patient, this would amount to well over $2
billion annually. To this figure, one would have to add the
overall costs for risk stratification ($300 million/year) as
well as the ongoing costs associated with ICDs. Thus, it can
be seen that even a risk-stratification scheme that is reason-
ably effective at identifying high-risk patients will lead to
high costs and to many patients receiving an ICD who do
not require one.
In conclusion, the present study by Bailey et al. (22) is the
first to conduct a meta-analysis of diagnostic tests thought
to be predictive of post-MI arrhythmic events. Using pooled
diagnostic test characteristics, the investigators have arrived
at a risk-stratification algorithm that may be more reliable
than those previously reported. Nevertheless, much work
needs to be done in this important area. Even the staged
approach advocated by the researchers is inadequate for
population-based risk stratification. The approach has not
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been tested prospectively in randomized clinical trials,
would be immensely costly to implement, and would lead to
large numbers of patients receiving ICDs who would never
need them. Nevertheless, Bailey et al. (22) have made an
important contribution. Their findings will doubtless serve
as a springboard for future studies examining the issue of
risk stratification for arrhythmic events following acute MI.
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